Zymeworks (ZYME) Earnings Date & Reports

Key Takeaways

• Total revenue surged to $256.5 million in the third quarter of 2026, up from $27.6 million in the same period a year earlier.
• Net income reached $173.7 million, a sharp turnaround from a net loss of $19.6 million in Q3 2025.
• The jump was driven largely by a $250.0 million milestone payment from partner Jazz Pharmaceuticals following U.S. approval of Ziihera.
• Adjusted earnings of $2.28 per share came in below the Zacks Consensus Estimate of $2.40, while revenue beat expectations.
• Zymeworks raised its full-year 2026 guidance, lifting both revenue and adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) targets.
• The quarter also reflected early integration costs from the Theravance Biopharma acquisition, which closed in September.
• For more context on the latest developments, explore Major News, Today's Price Move, Price Targets, and Forecast.
• Discover automated trading ideas through Trending AI Robots.

Earnings Context and Why It Matters

Zymeworks' third-quarter 2026 results arrive at a pivotal moment for the biotech's strategy of pairing a royalty-generating asset portfolio with an internal drug development engine. The period captures both a landmark regulatory event and a major corporate transaction. In August 2026, partner Jazz Pharmaceuticals secured U.S. Food and Drug Administration approval for Ziihera in first-line HER2-positive (a protein that drives certain tumor growth) gastroesophageal adenocarcinoma (GEA), triggering a substantial milestone. Weeks later, Zymeworks completed its acquisition of Theravance Biopharma. These events make the quarter's headline figures unusual, as one-time milestones and acquisition costs distort comparisons with prior periods. For investors, the report is less about routine operating trends and more about how these strategic moves reshape revenue, expenses, and cash flow visibility.

Reported Results

Zymeworks reported total revenue of $256.5 million for the quarter ended September 30, 2026, compared with $27.6 million a year earlier. The increase primarily reflected the $250.0 million milestone earned from Jazz following U.S. approval of Ziihera for first-line HER2-positive GEA, partly offset by the absence of a $25.0 million development milestone from Johnson & Johnson Innovative Medicine recognized in Q3 2025. Theravance Biopharma contributed roughly $1.5 million of revenue during its seven days of ownership.

The company posted net income of $173.7 million, versus a net loss of $19.6 million in the prior-year quarter. Research and development (R&D) expenses were $36.1 million (up slightly from $35.6 million), while selling, general, and administrative (SG&A) expenses rose to $42.7 million from $14.1 million, driven by acquisition-related severance, transaction fees, and higher stock-based compensation. Other income swung to a net expense of $4.4 million, reflecting interest on royalty-backed financing with Royalty Pharma.

On an adjusted basis, Zacks reported earnings of $2.28 per share, below the consensus estimate of $2.40, while revenue of $256.46 million surpassed expectations. Zymeworks also raised 2026 guidance to $337 million–$351 million in total revenue and $176 million–$190 million in adjusted EBITDA.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF (exchange-traded fund) discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable criteria such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors following names like Zymeworks across the biotechnology space, the AI Screener offers a structured way to compare candidates and monitor shifting conditions.

Market Reaction and Investor Sentiment

Investor attention around this report centered on two competing forces: an exceptionally strong headline quarter and an adjusted EPS figure that fell short of elevated consensus expectations. The $250 million Ziihera milestone pushed reported results well beyond any prior quarter, but the adjusted per-share miss reflects the difficulty analysts had modeling a period distorted by one-time items and acquisition costs. Sentiment also incorporates the company's raised 2026 guidance and its recently announced global collaboration with Roche on ZW209, which added an upfront payment, milestone potential, and royalty economics. Share repurchases, with roughly $279.8 million deployed cumulatively since August 2024, signal management confidence in the balance sheet. Zymeworks does not host a conference call for this quarter, leaving the press release as the primary driver of interpretation.

Forward Outlook and Key Factors to Monitor

Looking ahead, investors will focus on execution across Zymeworks' newly expanded portfolio. The integration of Theravance Biopharma adds commercial and near-commercial assets, including YUPELRI collaboration revenue, which grew modestly year over year. Watch whether acquisition-related costs moderate in coming quarters and whether the combined business can sustain operational momentum alongside higher SG&A.

A second area to monitor is the ZW209 collaboration with Roche. Pending Hart-Scott-Rodino clearance, this agreement carries an upfront payment and significant milestone potential, offering another source of non-dilutive funding if development advances. Progress here could shape how investors value the internal pipeline beyond the existing Ziihera franchise.

Finally, the revised full-year guidance provides a clearer near-term benchmark. With total revenue now guided to $337 million–$351 million and adjusted EBITDA to $176 million–$190 million, investors will assess whether milestone timing, integration costs, and royalty-backed interest expense keep results within these ranges. Clinical and regulatory catalysts across the company's programs remain key swing factors in the quarters ahead.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations